Mexiletine-like cellular electrophysiological effects of GS967 in canine ventricular myocardium by Hézső, Tamás et al.
1
Vol.:(0123456789)




of GS967 in canine ventricular 
myocardium
Tamás Hézső1,10, Muhammad Naveed2,10, Csaba Dienes1, Dénes Kiss1, János Prorok2,3, 
Tamás Árpádffy‑Lovas2, Richárd Varga2, Erika Fujii1, Tanju Mercan4, Leila Topal2, 
Kornél Kistamás1, Norbert Szentandrássy1,5, János Almássy1, Norbert Jost2,3, 
János Magyar1,6, Tamás Bányász1, István Baczkó2,7, András Varró2,3,7*, Péter P. Nánási1,8*, 
László Virág2,7,11 & Balázs Horváth1,9,11
Enhancement of the late  Na+ current  (INaL) increases arrhythmia propensity in the heart, while 
suppression of the current is antiarrhythmic. GS967 is an agent considered as a selective blocker of 
 INaL. In the present study, effects of GS967 on  INaL and action potential (AP) morphology were studied 
in canine ventricular myocytes by using conventional voltage clamp, action potential voltage clamp 
and sharp microelectrode techniques. The effects of GS967 (1 µM) were compared to those of the class 
I/B antiarrhythmic compound mexiletine (40 µM). Under conventional voltage clamp conditions,  INaL 
was significantly suppressed by GS967 and mexiletine, causing 80.4 ± 2.2% and 59.1 ± 1.8% reduction 
of the densities of  INaL measured at 50 ms of depolarization, and 79.0 ± 3.1% and 63.3 ± 2.7% reduction 
of the corresponding current integrals, respectively. Both drugs shifted the voltage dependence of the 
steady‑state inactivation curve of  INaL towards negative potentials. GS967 and mexiletine dissected 
inward  INaL profiles under AP voltage clamp conditions having densities, measured at 50% of AP 
duration (APD), of −0.37 ± 0.07 and −0.28 ± 0.03 A/F, and current integrals of −56.7 ± 9.1 and −46.6 ± 5.5 
mC/F, respectively. Drug effects on peak  Na+ current  (INaP) were assessed by recording the maximum 
velocity of AP upstroke  (V+max) in multicellular preparations. The offset time constant was threefold 
faster for GS967 than mexiletine (110 ms versus 289 ms), while the onset of the rate‑dependent 
block was slower in the case of GS967. Effects on beat‑to‑beat variability of APD was studied in 
isolated myocytes. Beat‑to‑beat variability was significantly decreased by both GS967 and mexiletine 
(reduction of 42.1 ± 6.5% and 24.6 ± 12.8%, respectively) while their shortening effect on APD was 
comparable. It is concluded that the electrophysiological effects of GS967 are similar to those of 
mexiletine, but with somewhat faster offset kinetics of  V+max block. However, since GS967 depressed 
 V+max and  INaL at the same concentration, the current view that GS967 represents a new class of drugs 
that selectively block  INaL has to be questioned and it is suggested that GS967 should be classified as a 
class I/B antiarrhythmic agent.
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Following the large  Na+ current surge associated with the AP upstroke (called  INaP) a smaller but sustained cur-
rent component (called  INaL) remains active throughout the entire cardiac AP. Enhanced  INaL, due to diseases 
like heart  failure1–3, hypertrophic  cardiomyopathy4 or  LQT35, is known to increase arrhythmia propensity in 
the  heart1,6–8. It has been known for a long time that many of the class I antiarrhythmic drugs inhibit  INaL in 
addition to blocking  INaP9–14. This latter effect, however, was considered to enhance proarrhythmic risk and 
consequently the incidence of sudden cardiac  death15. As a consequence, development of agents to suppress  INaL 
selectively was a straightforward strategy in the past  decades2,16–19. One of these agents, 6-(4-(trifluoromethoxy)
phenyl)-3-(trifluoromethyl)-[l,2,4]triazolo[4,3-a]pyridine, known as GS967 or GS458967, was reported to be a 
particularly selective candidate when tested in rabbit ventricular  cells16. It was also shown that important species-
dependent variations existed in the electrophysiological properties of myocardial  preparations20,21, and canine 
ventricular myocytes are considered a reasonably good model for human ventricular  cells22–24. Furthermore, it 
was previously shown using the action potential voltage clamp technique that the kinetic properties of  INaL are 
similar in dogs and  humans20, while differing from those of other mammals including guinea pigs, rabbits and 
 pigs25–27. Therefore, we studied the effects of GS967 on  INaL and AP  V+max (the indicator of  INaP), comparing them 
to similar effects of the class I/B antiarrhythmic agent mexiletine in canine ventricular preparations. In this work, 
based on experimental evidence, we challenge the present concept that GS967 exerts a selective  INaL blocking 
effect, since it has very similar class I/B antiarrhythmic properties as mexiletine.
Methods
Animals. Adult mongrel dogs of either sex were anesthetized with i.m. injections of 10  mg/kg ketamine 
hydrochloride (Calypsol, Richter Gedeon, Hungary) + 1  mg/kg xylazine hydrochloride (Sedaxylan, Eurovet 
Animal Health BV, The Netherlands) according to a protocol approved by the local Animal Care Committees 
(license  No: 9/2015/DEMÁB at University of Debrecen; and I-74-15-2017, I-74-24-2017 at University of Szeged) 
and by the Department of Animal Health and Food Control of the Ministry of Agriculture and Rural Develop-
ment (XIII/3330/2017 and XIII/3331/2017). All animal procedures conform to the guidelines from Directive 
2010/63/EU of the European Parliament on the protection of animals used for scientific purposes and the Guide 
for the Care and Use of Laboratory Animals (USA NIH publication NO 85-23, revised 1996) The study was car-
ried out in compliance with the ARRIVE guidelines.
Isolation of cardiomyocytes. Single canine myocytes were obtained by enzymatic dispersion using the 
segment perfusion technique, as previously  described28. Briefly, a wedge-shaped section of the ventricular wall 
supplied by the LAD coronary artery was cannulated, dissected and perfused with a nominally  Ca2+-free Joklik 
solution (Minimum Essential Medium Eagle, Joklik Modification, Sigma-Aldrich Co. St. Louis, MO, USA) for a 
period of 5 min. After this, the tissue was perfused with Joklik solution supplemented with 1 mg/ml collagenase 
(Type II, Worthington Biochemical Co., Lakewood, NJ, USA; representing final activity of 224 U/ml) and 0.2% 
bovine serum albumin (Fraction V., Sigma) containing 50 µM  Ca2+ for 30 min. Finally, the normal external  Ca2+ 
concentration was gradually restored and the cells were stored at 15 °C in Minimum Essential Medium Eagle 
until use. The chemicals used in the experiments were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA), 
except for GS967, which was purchased from MedKoo Biosciences, Inc. (Morrisville, NC, USA).
Electrophysiology. Cells were placed in a plexiglass chamber under an inverted microscope, allowing for 
continuous superfusion with a modified Tyrode solution by gravity flow at a rate of 1–2 ml/min. The modified 
Tyrode solution contained (in mM): NaCl 121, KCl 4,  CaCl2 1.3,  MgCl2 1, HEPES 10,  NaHCO3 25, glucose 10 
at pH = 7.35, which was supplemented according to the actual experimental design. The osmolarity of this solu-
tion was 300 ± 3 mOsm, measured with a vapor pressure osmometer. In all experiments, the bath temperature 
was set to 37 ºC using a temperature controller (Cell MicroControls, Norfolk, VA, USA). Electrical signals were 
amplified and recorded (MultiClamp 700A or 700B, Molecular Devices, Sunnyvale, CA, USA) under the control 
of a pClamp 10 software (Molecular Devices) following analogue–digital conversion (Digidata 1440A or 1332, 
Molecular Devices). Electrodes, having tip resistances of 2–3 MΩ when filled with pipette solution, were manu-
factured from borosilicate glass. Transmembrane currents were recorded in whole-cell voltage clamp configura-
tion. The series resistance was typically 4–8 MΩ, and the measurement was discarded if it changed substantially 
during the experiment.
Action potential voltage clamp. Action potential voltage clamp experiments were performed according to the 
methods  described29,30. A previously recorded midmyocardial canine ventricular AP was applied as command 
signal and the current traces were recorded continuously in modified Tyrode solution before and after 5 min 
superfusion with the  Na+ channel inhibitor applied. The drug-sensitive current was obtained by subtracting the 
post-drug trace from the reference pre-drug trace. When measuring the effects of GS967 or mexiletine on  INaL, 
the experiments were performed in the presence of 1 µM nisoldipine + 1 µM E4031 + 100 µM chromanol 293B, 
added to the Tyrode solution, in order to eliminate any interference from  Ca2+ and  K+ currents. The pipette solu-
tion contained (in mM): K-aspartate 120, KCl 30, MgATP 3, HEPES 10,  Na2-phosphocreatine 3, EGTA 0.01, 
cAMP 0.002, KOH 10 at pH = 7.3 with an osmolarity of 285 mOsm. The amplitude of the dissected  INaL was 
evaluated at 50% duration of the  APD90 value of the command AP. When determining the current integral, the 
initial 20 ms after the AP upstroke was excluded from evaluation in order to eliminate the contribution of  INaP. In 
each experiment 20 consecutive current traces were averaged and analyzed in order to reduce the noise and the 
trace-to-trace fluctuations of action potential configuration. Ion currents were normalized to cell capacitance, 
determined in each cell by applying hyperpolarizations from +10 to −10 mV for 15 ms.
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9565  | https://doi.org/10.1038/s41598-021-88903-3
www.nature.com/scientificreports/
Conventional voltage clamp. Conventional voltage clamp experiments, using rectangular command pulses, 
were performed to study the effects of GS967 and mexiletine on  INaL at stable test potentials. The external solu-
tion was a HEPES-buffered Tyrode solution containing (in mM): NaCl 144,  NaH2PO4 0.4, KCl 4.0,  CaCl2 1.8, 
 MgSO4 0.53, glucose 5.5 and HEPES 5.0, at pH = 7.4) supplemented with 1 µM nisoldipine, 0.5 µM HMR-1556 
and 0.1 µM dofetilide in order to block  Ca2+ and  K+ currents. The composition of the pipette solution was (in 
mM): CsCl 125, TEACl 20, MgATP 5, EGTA 10, HEPES 10, at a pH = 7.2). Test pulses were clamped to −20 mV 
for 2 s from the holding potential of −120 mV before and after application of GS967 or mexiletine, while the 
total amount of  INaL was determined by pharmacological subtraction performed by a final superfusion with 
20 µM TTX. The amplitude of  INaL was evaluated at 50 ms after beginning the pulse. For determination of current 
integral the initial 20 ms was excluded from evaluation in order to minimize the contribution of  INaP. In order 
to study the voltage-dependence of steady-state inactivation of  INaL, test depolarizations to −20 mV were pre-
ceded by a set of 2 s long prepulses clamped to various voltages between −130 and −40 mV for 2 s. Peak currents 
measured after these prepulses  (Itest) were normalized to the peak current measured after the −130 mV prepulse 
 (Imax) and these  Itest/Imax ratios were plotted against the respective prepulse potentials. The data were fitted to the 
two-state Boltzmann function (y = 100/[1 + exp((x-V1/2)/k)]).
Recording of APs from multicellular preparations. Multicellular preparations (right ventricular papillary mus-
cles) were selected to prevent the limitations of isolated myocyte studies, like the absence of intercellular clefts 
or potential damage to channel proteins, allowing better representation of in vivo conditions. The experiments 
were performed as previously  described31. Briefly, transmembrane potentials were recorded using 3 M KCl filled 
sharp glass microelectrodes having tip resistance between 10 and 20 MΩ. These electrodes were connected to 
the input of a high impedance electrometer (MDE GmbH, Heidelberg, Germany). Preparations were paced by 
a pair of platinum electrodes using 1 ms wide rectangular current pulses with twice the threshold amplitude at 
37 °C. The pacing cycle length was set to 1 s for at least 60 min allowing the preparations to equilibrate before 
starting the experiment.
Following equilibration at 1 s cycle length, the cycle length was sequentially varied between 0.3 and 5 s. At 
each cycle length the 25th AP was recorded, and the cycle length was then changed. Under these conditions a 
quasi steady-state rate-dependence could rapidly be obtained. APs were digitized at 100 kHz using an ADA 3300 
data acquisition board (Real Time Devices Inc., State Collage, PA, USA) and stored for later analysis. After taking 
control records at each cycle length the preparations were superfused with either GS967 or mexiletine for 20 min 
and then the protocol was repeated. Efforts were made to maintain the same impalement throughout each experi-
ment. If, however, an impalement became dislodged, adjustment was attempted, but when the parameters of the 
re-established impalement deviated by more than 5% from the previous record, the experiment was discarded.
Restitution kinetics of the maximum rate of depolarization  (V+max) is considered as the indicator of the offset 
time constant. To determine the restitution time constant for  V+max the preparations were paced using a train of 
20 basic stimuli delivered at a basic cycle length of 1 s. Each train was followed by a single extra stimulus applied 
with successively longer coupling intervals. The train of basic stimuli was reinitiated following the delivery of the 
extra stimulus. In this way, each 20th basic AP was followed by a single extra AP occurring at gradually increas-
ing diastolic intervals. The diastolic interval was defined as the time from  APD90 of the last basic member of the 
train to the upstroke of the extra AP. Recovery curves were generated by plotting the  V+max of each extra AP as a 
function of the respective diastolic interval and data were fitted to a single exponential function.
Onset kinetics of drug action on  V+max were determined by stimulating the preparation at a cycle length of 
0.4 s following a few min period of rest and the initial 40 APs were recorded and data were plotted against the 
number of the analyzed AP within the train. The rate of development of block was obtained by monoexponential 
fitting of the  V+max values.
Determination of beat‑to‑beat variability of APD in isolated myocytes. Since beat-to-beat variability of APD is 
relatively small in multicellular preparations due to the balancing effect of the neighboring cells, these experi-
ments were performed in isolated myocytes. Series of 50 consecutive action potentials were analyzed to estimate 
the beat-to-beat variability of APD, defined as short term variability (SV), according to the following formula:
 where SV is short term variability,  APDi and  APDi+1 indicate the durations of the ith and i + 1th APs, respec-
tively, at 90% level of repolarization and  nbeats denotes the number of consecutive beats  analyzed32. Changes in 
SV were presented as Poincaré plots where 50 consecutive APD values are plotted, each against the duration of 
the previous AP.
Statistics. Results are expressed as mean ± SEM values, n denotes the number of myocytes or multicellular 
preparations studied. Statistical significance of differences was evaluated using one-way ANOVA followed by 
Student’s t-test for paired or unpaired data as pertinent. Differences were considered significant when p was less 
than 0.05. Data were processed, analyzed and figures were created in Excel (Microsoft Corp., Redmond, WA, 
USA), and Origin 2015 (Originlab Corp., Northampton, MA, USA).
Results
Effects of GS967 and mexiletine on  INaL using conventional voltage clamp. First, the effects of 
GS967 and mexiletine on  INaL were studied under conventional voltage clamp conditions by applying 2 s duration 
depolarizations to −20 mV from the holding potential of −120 mV (Fig. 1). 1 µM GS967 significantly reduced 
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the density of  INaL, measured at 50 ms after the beginning of the pulse (from −0.313 ± 0.05 to −0.062 ± 0.01 A/F, 
corresponding to an 80.4 ± 2.2% reduction in the 6 myocytes studied). For comparison, this parameter was also 
significantly decreased by 40 µM mexiletine from −0.385 ± 0.036 to −0.156 ± 0.014 A/F (reduction of 59.1 ± 1.8%, 
n = 12). Similar results were obtained when comparing the current integrals, i.e. the charge carried by the current 
with the exclusion of the initial 20 ms. As determined from the same experiments, the current integrals were sig-
nificantly decreased from −69.1 ± 7.9 to −15.4 ± 3.9 mC/F (79.0 ± 3.1% inhibition) by GS967 and from −76.4 ± 7.6 
to −26.7 ± 2.6 mC/F (63.3 ± 2.7% reduction) by mexiletine.
Since class I antiarrhythmics are known to modify inactivation kinetics of  INaP, the effects of 1 µM GS967 
and 40 µM mexiletine on the voltage dependence of steady-state inactivation of  INaL was also examined using a 
conventional prepulse protocol. The amplitude of  INaL was determined at 50 ms after beginning of the test-pulse. 
Both GS967 and mexiletine caused a significant leftward shift in the steady-state inactivation curve (Fig. 2). The 
 V0.5 value was shifted by −17.2 and −13.5 mV in the presence of GS967 and mexiletine, respectively. The slope 
factors of the curves were not influenced by GS967 or mexiletine.
Effects of GS967 and mexiletine under action potential voltage clamp conditions. Based on the 
non-equilibrium gating theory of Clancy et al., gating of the  Na+ channel is intimately influenced by the shape 
of the voltage protocol  applied33. Therefore, the effects of GS967 and mexiletine on  INaL were studied also under 
action potential voltage clamp conditions using canonic mid-myocardial APs as command signals. 1 µM GS967 
and 40 µM mexiletine dissected inward  INaL profiles having current densities (measured at 50% of  APD90) of 
−0.37 ± 0.07 and −0.28 ± 0.03 A/F, and current integrals of −56.7 ± 9.1 and −46.6 ± 5.5 mC/F, respectively. These 
differences, however, were not significant statistically. Since the  Ca2+ and  K+ currents were previously blocked in 
these experiments, the recorded current profiles are considered as  INaL inhibited by GS967 and mexiletine during 
a regular ventricular AP (Fig. 3A–C).
The total density and integral of  INaL in canine myocytes were estimated using concentration–response curves 
obtained with TTX, which was applied as a reference compound. The maximum value of the Hill-fit gave the 
total magnitude of  INaL (Fig. 3D,E). Comparing the respective current densities and integrals dissected by 1 µM 
GS967 and 40 µM mexiletine to these maximal values obtained with TTX, the inhibiting effects of GS967 and 
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Figure 1.  Effects of 1 µM GS967 (A,C) and 40 µM mexiletine (B,D) on  INaL under conventional voltage clamp 
conditions using test pulses of 2 s duration clamped to −20 mV from the holding potential of −120 mV. At the 
end of each experiment the cells were superfused with 20 µM TTX to dissect the remaining  INaL. Dashed lines 
indicate zero current level. (A,B) Representative superimposed analogue records. (C,D) Average  INaL densities 
(measured at 50 ms) and integrals (measured from 20 ms to 2 s). Symbols and bars are mean ± SEM, small dots 
represent individual data, numbers in parentheses indicate the number of myocytes studied, asterisks denote 
significant differences between data of the pre-drug control and the GS967- or mexiletine-treated groups.
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of total  INaL density, and 78% and 64% of total  INaL integral, respectively. More importantly, the current profiles 
dissected by GS967 and mexiletine were different in shape. The GS967-sensitive current decreased monotoni-
cally during the AP, similarly to the TTX-sensitive current (not shown), while the mexiletine-sensitive current 
displayed a saddle-like profile. This difference is likely attributable to the threefold faster dissociation of GS967 
than mexiletine from the  Na+ channel (see later).
Effects of GS967 and mexiletine on action potential upstroke. After determining the effects on 
 INaL, the actions of GS967 and mexiletine on  INaP were studied and compared. Since direct measurement of 
cardiac  INaP is difficult at 37 °C, the maximum velocity of depolarization during the action potential upstroke 
 (V+max) was used as an approximate, although not linear, measure of  INaP34–36. Due to the more physiological 
situation (e.g. higher stability) in multicellular cardiac preparations, these experiments were performed in right 
ventricular papillary muscles using sharp microelectrodes. As demonstrated in Fig.  4A,B, 40  µM mexiletine 
significantly reduced  V+max in the entire frequency range applied under steady-state conditions, while this effect 
of GS967 was significant only at the shortest cycle lengths of 0.3 and 0.4 s. This difference can well be explained 
by the faster offset kinetics of GS967 (Fig. 4C,D). The time constant of recovery of  V+max, determined following 
a constant 1 Hz stimulation was 110 ms for GS967, while almost three times longer, 289 ms for mexiletine. The 
onset kinetics of  V+max block was studied by application of a constant stimulation rate at 2.5 Hz and the initial 
40 APs were recorded. The onset rate constant was 5.3 AP for 1 µM GS967 and 2.6 AP for 40 µM mexiletine 
(Fig. 4E,F).
Effects of GS967 and mexiletine on APD. Although APD in right ventricular trabeculae was shortened 
by both GS967 and mexiletine in a reverse rate-dependent manner, this effect was statistically significant only at 
the longest constant cycle lengths above 1.5 s (Fig. 5).
Effects of GS967 and mexiletine on beat‑to‑beat variability of APD. Elevated beat-to-beat QT 
interval variability is a good predictor of ventricular arrhythmia in a wide variety of patients, while at a sin-
gle cell level it translates into beat-to-beat variability of APD (also called short term variability, SV) — both 
parameters are considered as indicators of proarrhythmic  risk37–40. In contrast to multicellular preparations, 
where the neighboring cells may effectively balance the individual differences in APD, SV is more pronounced 
in single cells, therefore the effects of GS967 and mexiletine were studied on SV in isolated ventricular cells, 
paced at a constant cycle length of 1 s. Under these conditions SV was significantly decreased by 1 µM GS967 
and 40 µM mexiletine (reduction of 1.01 ± 0.19 and 0.63 ± 0.02 ms, respectively, corresponding to 42.1 ± 6.5% 
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Figure 2.  Effects of 1 µM GS967 (A) and 40 µM mexiletine (B) on the voltage dependence of steady-state 
inactivation of  INaL, determined using a conventional prepulse-protocol presented in the insets. 2 s long 
prepulses, ranging from –130 to −40 mV were followed by a test pulse clamped to −20 mV for 2 s. Each  INaL 
amplitude  (Itest) was normalized to the peak current measured after the −130 mV prepulse  (Imax) and these 
 Itest/Imax ratios were plotted as a function of the corresponding prepulse-potential. Finally, data were fitted to 
a Boltzmann function and the results are given below the stead-state inactivation curves. Symbols and bars 
are mean ± SEM values, numbers in parentheses indicate the number of myocytes studied, asterisks denote 
significant differences between data of the pre-drug control and the GS967- or mexiletine-treated groups.
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(all p < 0.05 and n = 8). All these effects were largely reversible upon washout (Fig. 6). Since APD itself is also 
known to affect the magnitude of SV, the term of relative SV (RSV) was  introduced31,41. Accordingly, RSV = dSV 
/ dAPD, i.e. the change in SV is normalized to that of APD. The value of RSV was significantly higher for GS967 
than mexiletine (0.039 ± 0.007 versus 0.015 ± 0.007) predicting a better antiarrhythmic effectivity of GS967 than 
mexiletine.
Discussion
We studied and compared the effects of GS967 (1 µM) to those of the class I/B antiarrhythmic drug mexiletine 
(40 µM) on  INaL and  INaP in canine ventricular myocardium by combining the conventional microelectrode, volt-
age clamp and action potential voltage clamp techniques. It was found that GS967, which is generally considered 
as a selective blocker of  INaL16, inhibits  INaP as well, similarly to the class I/B antiarrhythmic drug mexiletine, but 
with higher potency. Based on the hypothetically selective  INaL blocker nature of GS967, the drug was previously 
mentioned as a novel class VI antiarrhythmic  agent42. However, without questioning the theoretical possibility 
of the concept for selective  INaL inhibition, an alternative approach should also be considered, since the concept 
whether  INaL can be blocked selectively is an interesting and still unresolved issue. There is evidence that  Na+ 
current in cardiac tissues may also be conducted by  Na+ channels other than the cardiac specific  Nav1.5 chan-
nels, which were suggested to contribute to both  INaP and  INaL. However, proper functional evidence for their 
role is still lacking while considerable interspecies differences were  observed43–51. If these channels play a role 
in  INaL but not in  INaP, their pharmacological inhibition may result in selective  INaL blockade. However, GS967 
has not been shown to inhibit these types of sodium channels but it was reported to inhibit cardiac type  Nav1.5 
 channels9,10. Therefore‚ it is difficult to estimate the relative contribution of neuronal type  Na+ channels to the 
GS967-sensitive current.
Nav1.5 channels have complex and multiple open and closed  states52 with different drug binding properties 
governing active, inactive and resting channel states. Accordingly, drugs interacting with the binding sites of 
the channels depending on their actual open or closed channel states may produce variable effects on  INaP and 
 INaL. For example, when a drug binds rapidly and with high affinity to open and inactivated channel states, and 
it dissociates rapidly from closed resting channel states, it would not inhibit  INaP but  INaL. This would be due to 
complete drug dissociation from its binding site in the resting closed states unless frequency was very high or 
at least the cycle length would be shorter than its dissociation from the channel. Consequently, whether a drug 
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Figure 3.  Effects of GS967 and mexiletine in isolated canine ventricular myocytes under action potential 
voltage clamp conditions. (A) Average membrane current profiles dissected by 1 µM GS967 and 40 µM 
mexiletine (in 7 myocytes in both cases), respectively, in the presence of 1 µM nisoldipine + 1 µM 
E4031 + 100 µM chromanol 293B. The command AP is shown above the current traces. (B) Current densities 
measured at 50% duration of  APD90 of the command AP. (C) Current integrals from which the initial 20 ms 
period was excluded. (D,E) Concentration-dependent effects of TTX on the density and integral of  INaL. The 
solid line was obtained by fitting data to the Hill equation. For conventional reasons the polarity was ignored in 
these latter plots. Symbols and bars denote mean ± SEM values, small dots represent individual data, numbers in 
parentheses indicate the number of myocytes studied.
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specific  INaP or  INaL binding sites. Present results and other recently published  data9,10 are consistent with this 
suggestion and do not support a mechanism which is based on specific  INaL inhibition that is distinctly different 
from class I/B antiarrhythmic actions described for drugs such as  mexiletine14,52,  lidocaine9,10,14,  amiodarone11 
and  ranolazine53. This approach is also in line with the reported high (38-fold) selectivity of ranolazine on  INaL 
over  INaP2, which is intermediate (13-fold) for  amiodarone3 and much lower (only threefold) for  flecainide54.
In our experiments, both GS967 and mexiletine significantly depressed  V+max at high stimulation rates. It was 
previously established that changes of  V+max and  INaP are not linear and a relatively modest decrease of  V+max can 
represent robust depression of  INaP35,36. Accordingly, the 20–30% reduction of  V+max measured in the present study 
in papillary muscle preparations (at pacing cycle lengths of 0.3–0.4 s) following GS967 and mexiletine application 
can represent a similar degree of  INaP depression as the measured 60–80% reduction of  INaL obtained in ventricular 
myocytes. Therefore, in theory, neither GS967 nor mexiletine can be considered as “selective”  INaL inhibitors. 
However, when therapy is concerned — assuming that decreased  INaP is proarrhythmic, while reduced  INaL is 
antiarrhythmic — GS967, which has about threefold faster offset kinetics, can be more beneficial than mexiletine 
since  INaP would be affected in a lesser extent than  INaL by GS967 at normal or moderately enhanced heart rates.
On the basis of present and other results it is clear that GS967 affects  INaP in a strongly rate- and moderately 
species-dependent fashion. Similarly to our results,  V+max was reduced by 0.3 µM GS967 in murine  myocytes55, 
while the same concentration of the drug failed to modify  V+max in canine Purkinje  strands56. On the other hand, 
GS967 shortened APD in a variety of preparations, including  rat57,58,  murine55,  rabbit16,59 and  human60 ventricular 
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Figure 4.  Effects of 1 µM GS967 (A,C,E) and 40 µM mexiletine (B,D,F) on the maximal rate of depolarization 
 (V+max) measured in canine right ventricular trabeculae. (A,B) Cycle length-dependent effects on  V+max under 
steady-state conditions. (C,D) Determination of offset kinetics of GS967 and mexiletine as indicated by the 
time-dependent restitution of  V+max. (E,F) Determination of the onset kinetics of the  V+max-block at 2.5 Hz. The 
respective protocols are shown in the insets — for further details see Methods section. Solid lines were obtained 
by monoexponential fitting. Symbols and bars are mean ± SEM, numbers in parentheses indicate the number 
of preparations studied, asterisks denote significant differences between data of the pre-drug control and the 
GS967- or mexiletine-treated groups.
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cells within a wide concentration range (0.1–1 µM) — similarly to the present observations in isolated canine 
ventricular cells. In our multicellular preparations, however, a significant APD shortening effect appeared only 
at cycle lengths longer than 1.5 s. This can be explained by the well-known higher drug-sensitivity of single cells 
comparing to multicellular preparations. The reduction of  INaL by GS967 may result the GS967-induced short-
ening of the elongated APD, reduction of the enhanced dispersion and short term variability of repolarization, 
changes often preceding torsade de pointes  arrhythmias38–40.
Taken together the present results and the literature, it is likely that a compound having kinetic proper-
ties similar to GS967 would be a very promising new antiarrhythmic agent, since several in vitro16–19,55–60 and 
in vivo57,61 studies support the potent antiarrhythmic activity of GS967. Its kinetic properties are better than those 
of mexiletine, as shown in this study, and also than those of  ranolazine9, agents known to suppress  INaL. GS967 
had high brain  penetration62, which can be utilized as a potential new antiepileptic  compound63, and caused a 
profound use-dependent block on all sodium channel isoforms studied, making the compound prone for possible 
central nervous system side effects. It is unclear at present whether the effects of GS967 on the nervous system 
preclude the use of this drug as an antiarrhythmic therapeutic, however, a new agent exhibiting the same kinetic 
properties of GS967 without CNS side effects would represent a promising candidate for future development.
In summary, GS967 —similarly to mexiletine— inhibited both the peak and late components of  Na+ current 
and decreased beat-to-beat variability of APD. Based on its kinetic properties, GS967 should be classified as a 
new potent class I/B antiarrhythmic agent. The results of the present study also suggest that investigations of 
“selective”  INaL inhibitors should be carried out through a wide range of stimulation rates since the effect of drugs 
like GS967 or mexiletine, that possess fast offset kinetics of  INaP inhibition, can be misinterpreted.
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Figure 5.  Cycle length-dependent effects of GS967 (A,C) and mexiletine (B,D) on AP duration measured at 
90% of repolarization  (APD90) in canine right ventricular trabeculae under steady-state conditions. During the 
experiments the cycle length was gradually changed between 0.3 and 5 s. (A,B) Representative superimposed 
analogue action potential pairs obtained at the constant pacing cycle length of 1 s before and after superfusion 
with 1 µM GS967 or 40 µM mexiletine. (C,D) Average rate-dependent APD values. Symbols and bars are 
mean ± SEM, numbers in parentheses indicate the number of preparations studied, asterisks denote significant 
differences between data of the pre-drug control and the GS967- or mexiletine-treated groups.
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Figure 6.  Reversible effects of GS967 (A–C) and mexiletine (D–F) on beat-to-beat variability of APD in 
isolated myocytes. Superimposed sets of action potentials (A,D) and Poincaré plots (B,E) obtained in control, 
following exposure to 1 µM GS967 or 40 µM mexiletine, and after washout of drugs. (C) and (F) show the 
average effects on beat-to-beat variability (SV) and APD. Symbols and bars are mean ± SEM, small dots 
represent individual data, numbers in parentheses indicate the number of myocytes studied, asterisks denote 
significant differences between data of the pre-drug control and the GS967- or mexiletine-treated groups.
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